Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Afamelanotide (MT-1) was approved by the EMA in 2014 and FDA in 2019 under the brand name Scenesse for erythropoietic protoporphyria
The success of Covered California means that Blue Shield of California is able to provide primary care services for all our members
It has the number "7" embossed on one side and "novo" on the other
The names and codes currently associated with retatrutide include: International Nonproprietary Name (INN): Retatrutide this is the official generic name assigned by the World Health Organisation (WHO) and recorded in the WHO INN list, to facilitate consistent identification across countries Development code: LY3437943 this alphanumeric identifier was assigned by Eli Lilly and Company, the pharmaceutical manufacturer developing the compound, and is frequently used in clinical trial documentation and scientific publications [1] [2] Descriptive terms: Sometimes referred to informally in research contexts as a GLP-1/GIP/glucagon triple agonist or a triagonist , though these are descriptive terms rather than formal names No proprietary brand name (such as those used for semaglutide Ozempic, Wegovy or tirzepatide Mounjaro) has been officially assigned or approved for retatrutide at the time of writing
US$ 21.76
US$ 20.72
US$ 24.74
US$ 20.26
